DMKPQ (DMK Pharmaceuticals) Beginning Cash Position: $0.67 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Beginning Cash Position?

DMK Pharmaceuticals DMKPQ -99.00% 16 Beginning Cash Position is $0.67 Mil as of Sep. 2023. GuruFocus rates DMKPQ with a GF Score™ of 16/100.

DMK Pharmaceuticals's Beginning Cash Position for the quarter that ended in Sep. 2023 was $0.67 Mil.

DMK Pharmaceuticals's quarterly Beginning Cash Position increased from Mar. 2023 ($1.11 Mil) to Jun. 2023 ($3.10 Mil) but then declined from Jun. 2023 ($3.10 Mil) to Sep. 2023 ($0.67 Mil).

DMK Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2020 ($8.70 Mil) to Dec. 2021 ($6.82 Mil) but then increased from Dec. 2021 ($6.82 Mil) to Dec. 2022 ($23.24 Mil).

DMK Pharmaceuticals Beginning Cash Position Related Terms

DMK Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Beginning Cash Position Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.33 19.27 8.70 6.82 23.24

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.17 2.48 1.11 3.10 0.67
DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.67 Mil mean?
DMK Pharmaceuticals (DMKPQ) has a Beginning Cash Position of $0.67 Mil as of Sep. 2023. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Beginning Cash Position too high?
DMK Pharmaceuticals' current Beginning Cash Position is $0.67 Mil. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Beginning Cash Position compare to CNNC and THCT?
DMK Pharmaceuticals' Beginning Cash Position of $0.67 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current Beginning Cash Position is $0.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Beginning Cash Position of $0.67 Mil. The current Beginning Cash Position is $0.67 Mil. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Beginning Cash Position is $0.67 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price